{
  "ticker": "PME.AX",
  "tickerShort": "PME",
  "company": "Pro Medicus",
  "sector": "Healthcare IT",
  "sectorSub": "Medical Imaging",
  "exchange": "ASX",
  "currency": "A$",
  "reportId": "PME-2026-001",
  "current_price": 125.96,
  "priceHistory": [
    282.52,
    279.9,
    297.14,
    286.09,
    285.81,
    283.31,
    283.51,
    273.19,
    263.08,
    253.25,
    261.38,
    259.35,
    262.4,
    265.05,
    254,
    255.93,
    229.19,
    228.25,
    231.49,
    234.08,
    234.72,
    232.99,
    232.87,
    239.05,
    223.58,
    229.9,
    229.89,
    227.74,
    210,
    201.8,
    199.79,
    199.22,
    198.81,
    202.73,
    189.77,
    176.88,
    188.14,
    188.29,
    204.07,
    202.6,
    212.92,
    209.52,
    204.01,
    207.17,
    205.33,
    208.68,
    210.78,
    218.63,
    224.56,
    229.41,
    234.27,
    238.53,
    234.07,
    241.02,
    237.17,
    245.13,
    251.66,
    254.11,
    265.2,
    270.35,
    271.28,
    273.94,
    278.27,
    279.44,
    282.86,
    274.74,
    274.48,
    274.6,
    278.59,
    282.03,
    278.18,
    282.01,
    281.87,
    282.55,
    283.33,
    280.82,
    276.03,
    283.48,
    279.35,
    279.1,
    270.5,
    274.37,
    272,
    276.76,
    274.08,
    276.81,
    272.31,
    279.34,
    277.04,
    277.73,
    280.58,
    285.08,
    281.68,
    285.2,
    307.39,
    307.89,
    309.98,
    314.2,
    314.68,
    317.69,
    317.34,
    317,
    324.74,
    330.13,
    330.48,
    327.98,
    321.51,
    328.25,
    323.98,
    319.92,
    320.85,
    320.44,
    323.21,
    319.77,
    321.89,
    313.99,
    313.48,
    316.31,
    319.68,
    319.85,
    308.5,
    304.77,
    303.2,
    297.15,
    315.69,
    313.5,
    317.72,
    318,
    307.57,
    306.91,
    306.41,
    303.44,
    302.38,
    306,
    300,
    298.81,
    298.96,
    294.67,
    290.81,
    296.35,
    298.23,
    299.52,
    298.3,
    297.08,
    298.7,
    298.45,
    294.14,
    300.93,
    294.88,
    298.81,
    313.29,
    320.04,
    317.9,
    307.36,
    309.13,
    301.77,
    301.61,
    308.29,
    306.21,
    308.69,
    314,
    304.22,
    298.2,
    300.29,
    298.02,
    305.55,
    288.33,
    287.01,
    292.4,
    292.64,
    285.6,
    286.86,
    288,
    284.39,
    281.81,
    281.78,
    282.18,
    281.64,
    269.31,
    263.34,
    263.61,
    261.6,
    258.28,
    254.57,
    253.9,
    252.62,
    257.75,
    254.9,
    257.21,
    255.49,
    248.83,
    259.36,
    251.14,
    250.37,
    253.04,
    251.32,
    260.01,
    260.09,
    261.44,
    266.69,
    266.54,
    262.18,
    259.92,
    254.33,
    251.83,
    249,
    246.67,
    247.55,
    237.49,
    232.99,
    234.43,
    233.69,
    226.05,
    219.6,
    214.86,
    217.37,
    222.3,
    232.17,
    225.68,
    224.04,
    222.9,
    220.87,
    222.63,
    215.3,
    213.76,
    215,
    215.92,
    210.21,
    213.36,
    209.66,
    212.41,
    206.39,
    202.9,
    189.1,
    186.55,
    178.37,
    177.45,
    180.92,
    190.17,
    186.28,
    181.69,
    184.12,
    178.15,
    177.56,
    166.35,
    164.93,
    157.62,
    161.17,
    167.66,
    118.22,
    116.97,
    125.96
  ],
  "reference": {
    "sharesOutstanding": 112,
    "analystTarget": null,
    "analystBuys": null,
    "analystHolds": null,
    "analystSells": null,
    "analystCount": null,
    "epsTrailing": 1.021,
    "epsForward": null,
    "divPerShare": 0,
    "reportingCurrency": "A$",
    "revenue": 0.213,
    "revenueGrowth": 31.9,
    "ebitdaMargin": 77.44,
    "employees": 132,
    "_anchors": {
      "price": 125.96,
      "marketCapStr": "14.1B",
      "drawdown": 62,
      "pe": 123.4
    }
  },
  "freshness": {
    "reviewDate": "10 February 2026",
    "daysSinceReview": 8,
    "priceAtReview": 162.64,
    "pricePctChange": -22.6,
    "nearestCatalyst": "1H FY26 Results â€” The Immediate Test",
    "nearestCatalystDate": "12 FEBRUARY 2026",
    "nearestCatalystDays": -6,
    "urgency": 75,
    "status": "CRITICAL",
    "badge": "critical"
  },
  "hypotheses": {
    "T1": {
      "label": "US Expansion Accelerates",
      "description": "Pro Medicus continues winning major US health system contracts, growing from ~10% to 25%+ market share over the next 5 years. Cloud-native architecture creates structural cost advantage competitors cannot replicate.",
      "plain_english": "Pro Medicus continues winning major US health system contracts, growing from ~10% to 25%+ market share over the next 5 years. Cloud-native architecture creates structural cost advantage competitors cannot replicate.",
      "what_to_watch": "Contract win rate sustained at FY25 levels or above",
      "upside": "Pro Medicus continues winning major US health system contracts, growing from ~10% to 25%+ market share over the next 5 years. Cloud-native architecture creates structural cost advantage competitors cannot replicate.",
      "risk_plain": null,
      "survival_score": 0.32,
      "status": "LOW",
      "weighted_inconsistency": null,
      "last_updated": "2026-02-17T22:25:04.291Z"
    },
    "T2": {
      "label": "Valuation Mean-Reversion",
      "description": "The 163x P/E contracts to a more conventional 50-80x as growth decelerates or market sentiment shifts. Even extraordinary business quality has a price.",
      "plain_english": "The 163x P/E contracts to a more conventional 50-80x as growth decelerates or market sentiment shifts. Even extraordinary business quality has a price.",
      "what_to_watch": null,
      "upside": null,
      "risk_plain": "The 163x P/E contracts to a more conventional 50-80x as growth decelerates or market sentiment shifts. Even extraordinary business quality has a price.",
      "survival_score": 0.22,
      "status": "LOW",
      "weighted_inconsistency": null,
      "last_updated": "2026-02-17T22:25:04.291Z"
    },
    "T3": {
      "label": "Competitive Disruption",
      "description": "A competitor (existing or new entrant) develops a platform that matches Visage 7's cloud-native architecture, eroding Pro Medicus's structural advantage.",
      "plain_english": "A competitor (existing or new entrant) develops a platform that matches Visage 7's cloud-native architecture, eroding Pro Medicus's structural advantage.",
      "what_to_watch": null,
      "upside": null,
      "risk_plain": "A competitor (existing or new entrant) develops a platform that matches Visage 7's cloud-native architecture, eroding Pro Medicus's structural advantage.",
      "survival_score": 0.14,
      "status": "VERY_LOW",
      "weighted_inconsistency": null,
      "last_updated": "2026-02-17T22:25:04.291Z"
    },
    "T4": {
      "label": "AI Amplifies the Moat",
      "description": "Pro Medicus becomes the platform on which AI radiology tools run, deepening stickiness and expanding per-study economics. Platform companies historically capture more value than point-solution vendors.",
      "plain_english": "Pro Medicus becomes the platform on which AI radiology tools run, deepening stickiness and expanding per-study economics. Platform companies historically capture more value than point-solution vendors.",
      "what_to_watch": null,
      "upside": "Pro Medicus becomes the platform on which AI radiology tools run, deepening stickiness and expanding per-study economics. Platform companies historically capture more value than point-solution vendors.",
      "risk_plain": null,
      "survival_score": 0.32,
      "status": "LOW",
      "weighted_inconsistency": null,
      "last_updated": "2026-02-17T22:25:04.291Z"
    }
  },
  "dominant": "T1",
  "confidence": "LOW",
  "alert_state": "NORMAL",
  "alert_started": null,
  "presentation": {
    "heroDescription": "Medical Imaging &bull; Visage 7 Platform &bull; 132 Employees",
    "heroCompanyDescription": "Pro Medicus (ASX: PME) is a Melbourne-based medical imaging technology company whose Visage 7 platform provides ultra-fast diagnostic image viewing and AI-integrated radiology workflows to hospitals globally. With just 132 employees generating 77% EBITDA margins, Pro Medicus is one of the most capital-efficient healthcare IT companies in the world.",
    "heroMetrics": [
      {
        "label": "Mkt Cap",
        "value": "A$14.1B",
        "colorClass": ""
      },
      {
        "label": "P/E",
        "value": "163x",
        "colorClass": "premium"
      },
      {
        "label": "Rev Growth",
        "value": "+32%",
        "colorClass": "positive"
      },
      {
        "label": "EBITDA Mgn",
        "value": "77%",
        "colorClass": "positive"
      },
      {
        "label": "Debt",
        "value": "Zero",
        "colorClass": "positive"
      }
    ],
    "skew": {
      "direction": "upside",
      "rationale": "Exceptional business economics: 77% EBITDA margins, zero debt, A$1.6M revenue per employee. US market share only ~10% with A$520M in new contracts signed FY25. Extreme valuation but extraordinary quality."
    },
    "verdict": {
      "text": "The most extraordinary business on the ASX: Visage 7 generates 77% EBITDA margins with 132 employees (A$1.6M rev/head). Zero debt, A$211M cash, A$520M in new FY25 contracts including Trinity Health (A$330M) and UCHealth (A$170M). Revenue grew 32%, NPAT up 39%. US market share only ~10%. Morningstar's A$36 fair value is analytically questionable for a platform business with this quality of economics.",
      "borderColor": "var(--signal-green)",
      "scores": [
        {
          "label": "T1 US Expand",
          "score": "60%",
          "scoreColor": "var(--signal-green)",
          "dirArrow": "&uarr;",
          "dirText": "Strong",
          "dirColor": "var(--signal-green)"
        },
        {
          "label": "T2 Valuation",
          "score": "35%",
          "scoreColor": "var(--signal-amber)",
          "dirArrow": "&rarr;",
          "dirText": "Steady",
          "dirColor": null
        },
        {
          "label": "T3 Compete",
          "score": "20%",
          "scoreColor": "var(--text-muted)",
          "dirArrow": "&darr;",
          "dirText": "Weakening",
          "dirColor": "var(--signal-green)"
        },
        {
          "label": "T4 AI Moat",
          "score": "50%",
          "scoreColor": "var(--signal-green)",
          "dirArrow": "&uarr;",
          "dirText": "Rising",
          "dirColor": "var(--signal-green)"
        }
      ]
    },
    "featuredMetrics": [
      {
        "label": "Mkt Cap",
        "value": "A$14.1B",
        "color": ""
      },
      {
        "label": "P/E",
        "value": "163x",
        "color": ""
      },
      {
        "label": "Rev Growth",
        "value": "+32%",
        "color": "var(--signal-green)"
      },
      {
        "label": "EBITDA Mgn",
        "value": "77%",
        "color": "var(--signal-green)"
      }
    ],
    "featuredPriceColor": "var(--signal-green)",
    "featuredRationale": "Exceptional business: 77% EBITDA margins, zero debt, A$520M new contracts FY25. US market share only 10%. Extreme valuation but extraordinary economics.",
    "identity": {
      "rows": [
        [
          [
            "Ticker",
            "PME.AX",
            "td-mono"
          ],
          [
            "Exchange",
            "ASX",
            "td-mono"
          ]
        ],
        [
          [
            "Market Cap",
            "A$18.59B",
            "td-mono"
          ],
          [
            "Sector",
            "Healthcare IT",
            "td-mono"
          ]
        ],
        [
          [
            "Share Price",
            "A$125.96",
            "td-mono"
          ],
          [
            "52-Week Range",
            "A$161.64 &ndash; A$336.00",
            "td-mono"
          ]
        ],
        [
          [
            "P/E Ratio",
            "163x",
            "td-mono td-amber"
          ],
          [
            "EBITDA Margin",
            "77.44%",
            "td-mono td-green"
          ]
        ],
        [
          [
            "Revenue (FY25)",
            "A$212.98M (+31.9%)",
            "td-mono td-green"
          ],
          [
            "NPAT (FY25)",
            "A$115.22M (+39.2%)",
            "td-mono td-green"
          ]
        ],
        [
          [
            "Revenue/Employee",
            "A$1.6M",
            "td-mono td-green"
          ],
          [
            "Employees",
            "132",
            "td-mono"
          ]
        ],
        [
          [
            "Debt",
            "Zero",
            "td-mono td-green"
          ],
          [
            "Cash",
            "A$211M",
            "td-mono"
          ]
        ],
        [
          [
            "Core Product",
            "Visage 7 (Cloud-native imaging)",
            ""
          ],
          [
            "Recurring Revenue",
            "90%+",
            "td-mono td-green"
          ]
        ],
        [
          [
            "FY25 New Contracts",
            "A$520M",
            "td-mono td-green"
          ],
          [
            "US Market Share",
            "~10%",
            "td-mono"
          ]
        ],
        [
          [
            "CEO",
            "Dr Sam Hupert (Co-founder)",
            ""
          ],
          [
            "Next Earnings",
            "12 Feb 2026",
            "td-mono"
          ]
        ]
      ],
      "overview": "Melbourne-based medical imaging software company. Visage 7 platform provides radiology information systems (RIS) and picture archiving (PACS) to hospitals and health systems. Cloud-native architecture means zero per-study hosting costs, creating operating leverage as imaging volumes grow. Key FY25 contract wins: Trinity Health (A$330M, 7,600-bed system) and UCHealth (A$170M)."
    },
    "hypotheses": [
      {
        "tier": "t1",
        "direction": "upside",
        "title": "T1: US Expansion Accelerates",
        "statusClass": "accumulating",
        "statusText": "Evidence Building",
        "score": "60%",
        "scoreWidth": "60%",
        "scoreMeta": "&uarr; Strong",
        "description": "Pro Medicus continues winning major US health system contracts, growing from ~10% to 25%+ market share over the next 5 years. Cloud-native architecture creates structural cost advantage competitors cannot replicate.",
        "requires": [
          "Contract win rate sustained at FY25 levels or above",
          "No material contract losses",
          "Implementation timelines met for Trinity Health and UCHealth",
          "US sales team execution continues",
          "New product features (AI integration, workflow tools) deepen competitive advantage"
        ],
        "supportingLabel": "Supporting Evidence",
        "supporting": [
          "<strong>Filings:</strong> A$520M in new FY25 contracts (record). Trinity Health A$330M, UCHealth A$170M",
          "<strong>Competitor:</strong> US market share only ~10%. Competitor platforms are aging legacy systems",
          "<strong>Academic:</strong> 7-10 year switching cycles create long visibility on won contracts",
          "<strong>Filings:</strong> Cloud-native architecture provides structural cost advantage. 90%+ recurring revenue"
        ],
        "contradictingLabel": "Contradicting Evidence",
        "contradicting": [
          "<strong>Competitor:</strong> Market penetration may slow beyond \"early adopter\" health systems",
          "<strong>Competitor:</strong> GE, Philips, Siemens could rebuild cloud-native platforms",
          "<strong>Economic:</strong> Concentration risk in US health system market"
        ]
      },
      {
        "tier": "t2",
        "direction": "downside",
        "title": "T2: Valuation Mean-Reversion",
        "statusClass": "active",
        "statusText": "Active &mdash; Persistent Risk",
        "score": "35%",
        "scoreWidth": "35%",
        "scoreMeta": "&rarr; Steady",
        "description": "The 163x P/E contracts to a more conventional 50-80x as growth decelerates or market sentiment shifts. Even extraordinary business quality has a price.",
        "requires": null,
        "supportingLabel": "Supporting Evidence",
        "supporting": [
          "<strong>Broker:</strong> 163x P/E is in the top 1% of global healthcare IT multiples",
          "<strong>Media:</strong> Stock already corrected 51% from peak. Morningstar fair value A$36",
          "<strong>Economic:</strong> Rising interest rates pressure long-duration growth stocks",
          "<strong>Academic:</strong> Law of large numbers: harder to sustain 30%+ growth as revenue scales"
        ],
        "contradictingLabel": "Contradicting Evidence",
        "contradicting": [
          "<strong>Filings:</strong> PME has consistently defied valuation gravity by beating expectations",
          "<strong>Filings:</strong> Genuine operating leverage (margins expand with volume). Zero debt, strong FCF",
          "<strong>Academic:</strong> Companies with PME-like economics (77% EBITDA, zero debt) rarely mean-revert"
        ]
      },
      {
        "tier": "t3",
        "direction": "downside",
        "title": "T3: Competitive Disruption",
        "statusClass": "minimal",
        "statusText": "Minimal Evidence",
        "score": "20%",
        "scoreWidth": "20%",
        "scoreMeta": "&darr; Weakening",
        "description": "A competitor (existing or new entrant) develops a platform that matches Visage 7's cloud-native architecture, eroding Pro Medicus's structural advantage.",
        "requires": null,
        "supportingLabel": "Supporting Evidence",
        "supporting": [
          "<strong>Competitor:</strong> GE and Siemens have vast R&amp;D budgets",
          "<strong>Competitor:</strong> AI-focused imaging startups exist (Aidoc, Viz.ai)",
          "<strong>Academic:</strong> Technology advantages can be replicated given sufficient time and investment"
        ],
        "contradictingLabel": "Contradicting Evidence",
        "contradicting": [
          "<strong>Competitor:</strong> On-premise to cloud-native rebuild is multi-year, multi-billion dollar",
          "<strong>Competitor:</strong> No competitor has announced such an initiative. Legacy bases create massive inertia",
          "<strong>Alt Data:</strong> KLAS ratings confirm continued customer satisfaction leadership",
          "<strong>Academic:</strong> 20+ year head start on cloud architecture is not easily replicated"
        ]
      },
      {
        "tier": "t4",
        "direction": "upside",
        "title": "T4: AI Amplifies the Moat",
        "statusClass": "accumulating",
        "statusText": "Evidence Building",
        "score": "50%",
        "scoreWidth": "50%",
        "scoreMeta": "&uarr; Rising",
        "description": "Pro Medicus becomes the platform on which AI radiology tools run, deepening stickiness and expanding per-study economics. Platform companies historically capture more value than point-solution vendors.",
        "requires": null,
        "supportingLabel": "Supporting Evidence",
        "supporting": [
          "<strong>Academic:</strong> Cloud-native architecture inherently better suited for AI integration",
          "<strong>Academic:</strong> AI augments radiologists (not replaces), increasing imaging volume throughput",
          "<strong>Corporate:</strong> Pro Medicus already integrating AI workflow features",
          "<strong>Academic:</strong> Platform companies historically capture more value than point-solution AI vendors"
        ],
        "contradictingLabel": "Contradicting Evidence",
        "contradicting": [
          "<strong>Academic:</strong> AI in radiology still early stage. FDA clearance pathway uncertain",
          "<strong>Competitor:</strong> AI could commoditise imaging platforms if AI becomes the primary value driver"
        ]
      }
    ],
    "narrative": {
      "theNarrative": "The market narrative is dominated by a single tension: <strong>extraordinary business quality vs extreme valuation</strong>. At 163x trailing P/E, the stock prices in years of flawless execution. Morningstar's fair value estimate of A$36 (implying 78% downside) represents the \"valuation sceptic\" camp. The stock has already corrected <span class=\"key-stat down\">51%</span> from its A$336 peak.",
      "priceImplication": {
        "label": "Embedded Assumptions at A$125.96",
        "content": "<strong>Growth decelerating:</strong> Revenue growth slowing from 32% toward 15-20% as contract pipeline normalises. <strong>Valuation compresses:</strong> 163x P/E contracts toward 80-100x range. <strong>Competition emerging:</strong> GE/Philips/Siemens rebuild cloud-native platforms. <strong>Key person risk:</strong> Founder CEO Sam Hupert (age 71) succession unknown."
      },
      "evidenceCheck": "The embedded bear thesis understates the structural nature of the business advantages. Visage 7's cloud-native architecture means zero per-study hosting costs: as hospital imaging volumes grow (5-7% annually), margins expand without proportional cost increases. This is genuine <strong>operating leverage</strong>, not just growth. The company's 90% recurring revenue, zero debt, and <span class=\"key-stat\">A$520M</span> in new FY25 contracts suggest the flywheel is accelerating.",
      "narrativeStability": "<strong>Stable but vulnerable to valuation sentiment.</strong> The business quality narrative is well-established and supported by observable data. However, at 163x P/E, any miss on growth expectations would trigger a sharp re-rating. The 1H FY26 results on 12 February 2026 are the immediate test."
    },
    "evidence": {
      "intro": "Ten evidence domains assessed. The evidence is overwhelmingly positive on business quality, with the only credible bear case being valuation.",
      "cards": [
        {
          "number": 1,
          "title": "1. Corporate Communications",
          "epistemicClass": "ep-motivated",
          "epistemicLabel": "Motivated",
          "finding": "<strong>Finding:</strong> Management communications emphasise contract wins, market expansion, and product differentiation. FY25 results highlighted A$520M in new contracts (record year), 32% revenue growth, and 39% NPAT growth. CEO Sam Hupert and CFO consistently undersell relative to delivery. Management tone is unusually restrained for a company growing 30%+; this is itself a positive signal for credibility.",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Supports",
              "class": "supports"
            },
            {
              "text": "T4: Supports",
              "class": "supports"
            }
          ],
          "source": null
        },
        {
          "number": 2,
          "title": "2. Regulatory Filings",
          "epistemicClass": "ep-statutory",
          "epistemicLabel": "Under Oath / Statutory",
          "finding": "<strong>Finding:</strong> FY25: Revenue A$212.98M (+31.9%), NPAT A$115.22M (+39.2%), EBITDA margin 77.44%. Zero debt. Cash A$211M. 90%+ recurring revenue. Contract announcements: Trinity Health A$330M (7,600-bed system), UCHealth A$170M. FY25 new contract value A$520M, up from A$196M prior year. Dividend payout ratio ~60%, growing in line with earnings. No dilutive capital raises. Balance sheet is pristine.",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Supports",
              "class": "supports"
            },
            {
              "text": "T2: Weakens",
              "class": "contradicts"
            },
            {
              "text": "T4: Supports",
              "class": "supports"
            }
          ],
          "source": null
        },
        {
          "number": 3,
          "title": "3. Broker Research",
          "epistemicClass": "ep-consensus",
          "epistemicLabel": "Consensus",
          "finding": "<strong>Finding:</strong> Broker consensus is divided. Some analysts rate it a premium compounder with long runway; others see valuation risk. The wide range of price targets (A$150 to A$270+) reflects the fundamental disagreement on what multiple this business deserves. Morningstar's A$36 fair value is the extreme bear case, implying margins or growth must collapse. Few analysts have been willing to downgrade despite the 51% correction.",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Supports",
              "class": "supports"
            },
            {
              "text": "T2: Supports",
              "class": "supports"
            }
          ],
          "source": null
        },
        {
          "number": 4,
          "title": "4. Competitor Analysis",
          "epistemicClass": "ep-independent",
          "epistemicLabel": "Independent",
          "finding": "<strong>Finding:</strong> Key competitors: GE HealthCare (Centricity), Philips (IntelliSpace), Siemens Healthineers (syngo.via), Fujifilm (Synapse). All are on-premise legacy architectures requiring per-study storage costs. Pro Medicus's cloud-native approach creates a structural cost advantage that is difficult to replicate without a full platform rebuild. No competitor has achieved comparable margins. Market share data: Visage 7 holds ~10% of US radiology market; the top 4 incumbents hold ~70%. Switching cycles in healthcare imaging are 7-10 years, creating long visibility.",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Supports",
              "class": "supports"
            },
            {
              "text": "T3: Weakens",
              "class": "contradicts"
            }
          ],
          "source": null
        },
        {
          "number": 5,
          "title": "5. Economic Data",
          "epistemicClass": "ep-objective",
          "epistemicLabel": "Objective",
          "finding": "<strong>Finding:</strong> Medical imaging volume growth of 5-7% annually is a structural driver (ageing population, expanding clinical indications, preventive screening). US healthcare IT spending trending upward. CMS reimbursement rates for radiology are stable. No regulatory headwinds specific to imaging IT. Hospital consolidation creates larger potential customers for enterprise-wide platform deals.",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Supports",
              "class": "supports"
            },
            {
              "text": "T3: Weakens",
              "class": "contradicts"
            }
          ],
          "source": null
        },
        {
          "number": 6,
          "title": "6. Alternative Data",
          "epistemicClass": "ep-behavioural",
          "epistemicLabel": "Behavioural",
          "finding": "<strong>Finding:</strong> No insider selling signals. Founder CEO Dr Sam Hupert maintains significant shareholding. Employee count remarkably stable at ~132, suggesting the lean model is deliberate, not understaffed. Customer satisfaction data from KLAS Research (healthcare IT ratings) consistently places Visage 7 at or near the top. No negative Glassdoor signals.",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Supports",
              "class": "supports"
            },
            {
              "text": "T4: Supports",
              "class": "supports"
            }
          ],
          "source": null
        },
        {
          "number": 7,
          "title": "7. Academic Research",
          "epistemicClass": "ep-peerreviewed",
          "epistemicLabel": "Peer-Reviewed",
          "finding": "<strong>Finding:</strong> Academic literature on cloud-native platform advantages in enterprise software supports the thesis that architectural advantages compound over time. Research on AI in radiology consistently shows AI as a radiologist augmentation tool (not replacement), which benefits imaging platform providers who can embed AI workflows. Studies on healthcare IT switching costs confirm 7-10 year replacement cycles.",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Supports",
              "class": "supports"
            },
            {
              "text": "T4: Supports",
              "class": "supports"
            },
            {
              "text": "T3: Weakens",
              "class": "contradicts"
            }
          ],
          "source": null
        },
        {
          "number": 8,
          "title": "8. Media &amp; Social",
          "epistemicClass": "ep-noise",
          "epistemicLabel": "Noise",
          "finding": "<strong>Finding:</strong> Predominantly positive media coverage focused on contract wins and growth metrics. Financial media frequently cites PME as an example of \"quality growth\" on the ASX. The Morningstar A$36 valuation has generated significant discussion and scepticism about whether traditional valuation frameworks apply. Social media sentiment is mixed between \"incredible business\" and \"absurdly expensive.\"",
          "tension": null,
          "table": null,
          "tags": [
            {
              "text": "T1: Neutral",
              "class": "neutral"
            },
            {
              "text": "T2: Supports",
              "class": "supports"
            }
          ],
          "source": null
        },
        {
          "number": 9,
          "title": "9. Leadership &amp; Governance",
          "epistemicClass": "ep-governance",
          "epistemicLabel": "Independent Assessment",
          "finding": "<strong>Exceptional founder-led execution, but succession is the elephant in the room.</strong> Dr Sam Hupert (age ~71) has co-led Pro Medicus since 1983 and served as CEO since 2009. Under his leadership, PME has delivered one of the most remarkable growth stories on the ASX: from a small Australian medical imaging company to a global enterprise platform provider. His domain expertise as a radiologist gives PME an authentic product vision that pure software companies lack. Craig Hartnett has been instrumental in US expansion, bringing deep healthcare IT sales expertise from AGFA and Fuji. The company runs extraordinarily lean: ~132 employees globally, minimal bureaucracy, founder-led decision-making. <strong>Key risk: succession planning is opaque.</strong> Dr Hupert is 71; there is no disclosed succession plan, no COO, and no obvious internal heir apparent. The company's strategy and culture are deeply intertwined with its founder. Board is stable but small. Skin in the game is excellent: ~7% founder shareholding worth ~A$700M at current prices aligns interests completely.",
          "tension": "<strong>Tension:</strong> The very qualities that make PME exceptional (lean, founder-driven, no bureaucracy) are the same qualities that create key-person risk.",
          "table": {
            "headers": [
              "Name",
              "Role",
              "Tenure",
              "Shareholding",
              "Prior Experience"
            ],
            "rows": [
              [
                "Dr Sam Hupert",
                "CEO &amp; Co-founder",
                "Since 2009 (co-founded 1983)",
                "~7% (~A$700M)",
                "Radiologist; medical imaging entrepreneur"
              ],
              [
                "Peter Kempen",
                "Chairman",
                "Since 2007",
                "Moderate",
                "Deloitte; PE advisory"
              ],
              [
                "Craig Hartnett",
                "VP &amp; GM North America",
                "Since 2013",
                "Options vesting",
                "AGFA Healthcare; Fuji Medical; Philips"
              ]
            ]
          },
          "tags": [
            {
              "text": "Strongly Supports T1 (founder quality)",
              "class": "strong"
            },
            {
              "text": "Neutral on T2",
              "class": "neutral"
            },
            {
              "text": "Supports T4 (succession risk)",
              "class": "supports"
            }
          ],
          "source": "PME Annual Report FY25; ASX filings; healthcare IT industry analysis"
        },
        {
          "number": 10,
          "title": "10. Ownership &amp; Capital Flows",
          "epistemicClass": "ep-registry",
          "epistemicLabel": "Registry Data",
          "finding": "<strong>Tight register with quality holders, but valuation shorts are persistent.</strong> PME's register is unusually concentrated for a company of its market cap (~A$10B). Founder Sam Hupert's ~7% stake is a powerful alignment signal: he has never sold a share, and at ~A$700M, his interests are completely aligned with shareholders. Institutional holders are a mix of passive index (Vanguard, BlackRock, growing with ASX 200 weight increases) and quality-growth active managers (Hyperion, who have been long-term holders through multiple cycles). <strong>Short interest is material at ~4-5% of free float</strong>, driven almost entirely by valuation shorts: funds betting that 163x P/E must eventually compress. These shorts have been persistently wrong; PME has been one of the most costly short positions on the ASX over the past 3 years. The absence of institutional selling despite a 51% drawdown from peak suggests holders have conviction in the long-term thesis, not just momentum. <strong>Key insight:</strong> when quality holders are not selling into a drawdown, and shorts are elevated but not increasing, the register is telling you the smart money believes the thesis is intact even if the multiple is compressing.",
          "tension": null,
          "table": {
            "headers": [
              "Holder",
              "Type",
              "Stake",
              "Movement"
            ],
            "rows": [
              [
                "Dr Sam Hupert (CEO)",
                "Founder/Insider",
                "~7%",
                "Steady (long-term hold)"
              ],
              [
                "Vanguard Group",
                "Passive/Index",
                "~5.8%",
                "Increased (index inclusion)"
              ],
              [
                "BlackRock",
                "Passive/Index",
                "~4.5%",
                "Steady"
              ],
              [
                "Hyperion Asset Mgmt",
                "Active Growth",
                "~4.0%",
                "Long-term holder"
              ],
              [
                "Short sellers",
                "Bearish",
                "~4-5% SI",
                "Elevated (valuation shorts)"
              ]
            ]
          },
          "tags": [
            {
              "text": "Supports T1 (holder conviction)",
              "class": "supports"
            },
            {
              "text": "Supports T2 (shorts targeting valuation)",
              "class": "supports"
            },
            {
              "text": "Neutral on T3",
              "class": "neutral"
            }
          ],
          "source": "ASX substantial holder notices; ASIC short position reports; annual report top-20; insider transaction filings"
        }
      ],
      "alignmentSummary": null
    },
    "discriminators": {
      "intro": "Four data points carry high diagnosticity. Morningstar fair value estimates are non-discriminating.",
      "rows": [
        {
          "diagnosticity": "HIGH",
          "diagnosticityClass": "disc-high",
          "evidence": "<strong>1H FY26 results (12 Feb 2026).</strong> Revenue growth rate is the single most important signal.",
          "discriminatesBetween": "T1 (expansion accelerating) vs T2 (valuation correction)",
          "currentReading": "Awaiting &mdash; 2 days",
          "readingClass": "td-amber"
        },
        {
          "diagnosticity": "HIGH",
          "diagnosticityClass": "disc-high",
          "evidence": "<strong>New contract announcements.</strong> Each major health system win (A$100M+) extends the US penetration thesis.",
          "discriminatesBetween": "T1 (US growth) vs T3 (competitive disruption)",
          "currentReading": "A$520M won in FY25",
          "readingClass": "td-green"
        },
        {
          "diagnosticity": "MEDIUM",
          "diagnosticityClass": "disc-med",
          "evidence": "<strong>Competitor platform announcements.</strong> Any cloud-native initiative from GE, Philips, or Siemens.",
          "discriminatesBetween": "T3 (disruption real) vs T1 (moat holds)",
          "currentReading": "No initiatives announced",
          "readingClass": "td-green"
        },
        {
          "diagnosticity": "MEDIUM",
          "diagnosticityClass": "disc-med",
          "evidence": "<strong>AI feature releases and adoption.</strong> Evidence that Visage 7 is becoming the AI radiology platform layer.",
          "discriminatesBetween": "T4 (AI amplifies moat) vs T3 (AI commoditises)",
          "currentReading": "Early stage",
          "readingClass": "td-amber"
        }
      ],
      "nonDiscriminating": "<strong>\"Morningstar fair value A$36\"</strong> (DCF models structurally undervalue platform businesses with expanding margins; analytically questionable) &bull; <strong>\"163x P/E is expensive\"</strong> (tautological; describes the question, not the answer) &bull; <strong>\"Imaging volumes growing 5-7%\"</strong> (benefits all players equally)"
    },
    "tripwires": {
      "intro": "Three revision conditions with specific thresholds. Defined before the events occur to reduce rationalisation bias.",
      "cards": [
        {
          "date": "12 FEBRUARY 2026",
          "name": "1H FY26 Results &mdash; The Immediate Test",
          "conditions": [
            {
              "if": "If revenue growth &ge;25% and EBITDA margin holds above 75%",
              "valence": "positive",
              "then": "T1 (US Expansion) and T4 (AI Moat) strengthen. Growth flywheel confirmed."
            },
            {
              "if": "If revenue growth decelerates to &lt;20%",
              "valence": "negative",
              "then": "T2 (Valuation Mean-Reversion) strengthens. Growth maturation narrative gains credibility."
            },
            {
              "if": "If new contracts disclosed with AI-specific features",
              "valence": "positive",
              "then": "T4 strengthens. Platform-as-AI-layer thesis validated."
            }
          ],
          "source": "Source: ASX announcement; company earnings presentation"
        },
        {
          "date": "CY 2026",
          "name": "US Market Share Milestone",
          "conditions": [
            {
              "if": "If US market share grows from ~10% toward 15%",
              "valence": "positive",
              "then": "T1 materially confirmed. Addressable market thesis validated."
            },
            {
              "if": "If US market share stalls or a contract is lost to a competitor",
              "valence": "negative",
              "then": "T3 (Competitive Disruption) strengthens. Platform advantage may be narrower than assumed."
            }
          ],
          "source": "Source: Company disclosures; KLAS market share data"
        },
        {
          "date": "ONGOING",
          "name": "Competitor Platform Initiatives",
          "conditions": [
            {
              "if": "If GE, Philips, or Siemens announce cloud-native imaging platform rebuild",
              "valence": "negative",
              "then": "T3 strengthens (3-5 year horizon). Structural advantage has an expiry date."
            },
            {
              "if": "If incumbents continue with incremental upgrades to legacy platforms",
              "valence": "positive",
              "then": "T3 remains weak. Cloud-native moat deepens with each year of inaction."
            }
          ],
          "source": "Source: GE HealthCare, Philips, Siemens Healthineers corporate communications"
        }
      ]
    },
    "gaps": {
      "coverageRows": [
        {
          "domain": "Corporate Comms",
          "coverageLevel": "full",
          "coverageLabel": "Full",
          "freshness": "Current",
          "confidence": "Low (motivated)",
          "confidenceClass": ""
        },
        {
          "domain": "Regulatory",
          "coverageLevel": "full",
          "coverageLabel": "Full",
          "freshness": "Current",
          "confidence": "High (statutory)",
          "confidenceClass": "td-green"
        },
        {
          "domain": "Broker Research",
          "coverageLevel": "good",
          "coverageLabel": "Good",
          "freshness": "Current",
          "confidence": "Medium (divided)",
          "confidenceClass": "td-amber"
        },
        {
          "domain": "Competitor Data",
          "coverageLevel": "good",
          "coverageLabel": "Good",
          "freshness": "Structural",
          "confidence": "High (independent)",
          "confidenceClass": "td-green"
        },
        {
          "domain": "Economic Data",
          "coverageLevel": "good",
          "coverageLabel": "Good",
          "freshness": "Current",
          "confidence": "High (objective)",
          "confidenceClass": "td-green"
        },
        {
          "domain": "Alternative Data",
          "coverageLevel": "good",
          "coverageLabel": "Good",
          "freshness": "Current",
          "confidence": "High (KLAS ratings)",
          "confidenceClass": "td-green"
        },
        {
          "domain": "Academic Research",
          "coverageLevel": "good",
          "coverageLabel": "Good",
          "freshness": "Structural",
          "confidence": "High (peer-reviewed)",
          "confidenceClass": "td-green"
        },
        {
          "domain": "Media &amp; Social",
          "coverageLevel": "full",
          "coverageLabel": "Full",
          "freshness": "Current",
          "confidence": "Low (noise)",
          "confidenceClass": ""
        },
        {
          "domain": "Leadership &amp; Governance",
          "coverageLevel": "full",
          "coverageLabel": "Full",
          "freshness": "Current",
          "confidence": "High (founder-led, long track record)",
          "confidenceClass": "td-green"
        },
        {
          "domain": "Ownership &amp; Capital Flows",
          "coverageLevel": "good",
          "coverageLabel": "Good",
          "freshness": "Recent",
          "confidence": "High (clear registry signals)",
          "confidenceClass": "td-green"
        }
      ],
      "couldntAssess": [
        "<strong>Contract pipeline depth:</strong> Pro Medicus does not disclose total pipeline, only announced wins. The rate and size of future contract announcements is the key unknown. Whether the A$520M FY25 pace is sustainable or represents a one-off cluster is unobservable.",
        "<strong>Implementation success rates:</strong> Large health system implementations (e.g., Trinity Health's 7,600 beds) are complex and multi-year. Whether these proceed on schedule and budget is not publicly reported until problems emerge.",
        "<strong>Key person risk:</strong> Co-founder Dr Sam Hupert is 71. Succession planning is not publicly detailed. The company's lean model (132 employees for an A$14.1B company) creates concentration risk in key personnel."
      ],
      "analyticalLimitations": "Hypothesis survival scores (T1: 39%, T2: 25%, T3: 18%, T4: 18%) reflect the strong evidence asymmetry in this case. The high score for T1 (US Expansion) is driven by observable contract wins, market share data, and competitive positioning. The low score for T3 (Competitive Disruption) reflects the absence of any credible competitive threat in the near term. The Upside skew rating despite a 163x P/E is an editorial judgment: conventional valuation frameworks consistently undervalue platform businesses with this quality of economics. Whether the market agrees is a separate question from whether the evidence supports it."
    },
    "technicalAnalysis": {
      "date": "10 February 2026",
      "period": "1 Year",
      "source": "Continuum Technical Intelligence",
      "regime": "Trending",
      "clarity": "Clear",
      "price": {
        "current": 125.96,
        "currency": "A$"
      },
      "movingAverages": {
        "ma50": {
          "value": 212.7,
          "date": "10 Feb 2026"
        },
        "ma200": {
          "value": 269.57,
          "date": "10 Feb 2026"
        },
        "crossover": {
          "type": "Death Cross",
          "date": "w/c 22 September 2025",
          "description": "50-day MA crossed below 200-day MA"
        },
        "priceVsMa50": -21.8,
        "priceVsMa200": -38.3
      },
      "trend": {
        "direction": "Down",
        "duration": "8 months",
        "structure": "Lower highs, lower lows; occasional rally attempts fail at declining resistance",
        "peak": {
          "price": 330.48,
          "date": "w/c 14 July 2025"
        },
        "trough": {
          "price": 157.62,
          "date": "w/c 3 February 2026"
        },
        "drawdown": -49.7
      },
      "keyLevels": {
        "support": {
          "price": 157,
          "method": "Recent intraday low (Feb 2026)"
        },
        "resistance": {
          "price": 220,
          "method": "Prior support turned resistance (Dec 2025)"
        },
        "fiftyTwoWeekHigh": {
          "price": 330.48,
          "date": "w/c 14 July 2025"
        },
        "fiftyTwoWeekLow": {
          "price": 157.62,
          "date": "w/c 3 February 2026"
        }
      },
      "volume": {
        "latestVs20DayAvg": 1.8,
        "latestDate": "10 February 2026",
        "priorSpikes": [
          {
            "period": "w/c 22 September 2025",
            "ratio": 2.4,
            "context": "Death cross week; break below A$300"
          },
          {
            "period": "w/c 15 December 2025",
            "ratio": 2.1,
            "context": "Break below A$250; institutional selling"
          },
          {
            "period": "w/c 3 February 2026",
            "ratio": 2.6,
            "context": "Break below A$180; new 12-month low"
          }
        ]
      },
      "volatility": {
        "latestDailyRange": {
          "high": 167.66,
          "low": 157.62,
          "date": "10 February 2026"
        },
        "latestRangePercent": 6.4,
        "avgDailyRangePercent30": 3.2,
        "avgDailyRangePercent90": 2.1
      },
      "meanReversion": {
        "vsMa50": -21.8,
        "vsMa200": -38.3,
        "rangePosition": 5,
        "rangeHigh": 330.48,
        "rangeLow": 157.62
      },
      "inflectionPoints": [
        {
          "date": "w/c 14 July 2025",
          "price": 330.48,
          "event": "12-month high"
        },
        {
          "date": "w/c 22 September 2025",
          "price": 297.15,
          "event": "Death cross forms; break below A$300"
        },
        {
          "date": "w/c 3 November 2025",
          "price": 263.34,
          "event": "Break below A$270; selling accelerates"
        },
        {
          "date": "w/c 15 December 2025",
          "price": 246.67,
          "event": "Break below A$250"
        },
        {
          "date": "w/c 19 January 2026",
          "price": 214.86,
          "event": "Break below A$220; cascading stops"
        },
        {
          "date": "w/c 3 February 2026",
          "price": 157.62,
          "event": "New 12-month low; acceleration to downside"
        }
      ],
      "relativePerformance": {
        "vsIndex": {
          "name": "S&amp;P/ASX 200",
          "period": "12 months",
          "stockReturn": -43,
          "indexReturn": -2.3,
          "relativeReturn": -40.7
        },
        "vsSector": {
          "name": "S&amp;P/ASX Healthcare",
          "period": "12 months",
          "stockReturn": -43,
          "sectorReturn": -12.4,
          "relativeReturn": -30.6
        }
      }
    },
    "footer": {
      "disclaimer": "This report does not constitute personal financial advice. Continuum Intelligence synthesises cross-domain evidence using the Analysis of Competing Hypotheses (ACH) methodology. All factual claims are sourced from ASX filings, company disclosures, broker consensus data, and publicly available information. This report does not contain buy, sell, or hold recommendations, price targets, or valuation models.",
      "domainCount": "10 of 10",
      "hypothesesCount": "4 Active"
    }
  },
  "big_picture": "Pro Medicus (ASX: PME) is a Melbourne-based medical imaging technology company whose Visage 7 platform provides ultra-fast diagnostic image viewing and AI-integrated radiology workflows to hospitals globally. With just 132 employees generating 77% EBITDA margins, Pro Medicus is one of the most capital-efficient healthcare IT companies in the world.",
  "last_flip": null,
  "narrative_history": [],
  "evidence_items": [],
  "price_signals": [],
  "editorial_override": null,
  "weighting": null,
  "last_extracted": "2026-02-17T22:20:28.077Z",
  "last_updated": "10 February 2026",
  "last_research_update": "2026-02-17T22:25:04.291Z"
}